Abstract: Candida auris is an emerging pathogen with resistance to many commonly used antifungal agents. Infections with C. auris require rapid and reliable detection methods to initiate successful medical treatment and contain hospital outbreaks. Conventional identification methods are prone to errors and can lead to misidentifications. PCR-based assays, in turn, can provide reliable results with low turnaround times. However, only limited data are available on the performance of commercially available assays for C. auris detection. In the present study, the two commercially available PCR assays AurisID (OLM, Newcastle Upon Tyne, UK) and Fungiplex Candida Auris RUO Real-Time PCR (Bruker, Bremen, Germany) were challenged with 29 C. auris isolates from all five clades and eight other Candida species as controls. AurisID reliably detected C. auris with a limit of detection (LoD) of 1 genome copies/reaction. However, false positive results were obtained with high DNA amounts of the closely related species C. haemulonii, C. duobushaemulonii and C. pseudohaemulonii. The Fungiplex Candida Auris RUO Real-Time PCR kit detected C. auris with an LoD of 9 copies/reaction. No false positive results were obtained with this assay. In addition, C. auris could also be detected in human blood samples spiked with pure fungal cultures by both kits. In summary, both kits could detect C. auris-DNA at low DNA concentrations but differed slightly in their limits of detection and specificity.

Keywords: qPCR; detection limits; sensitivity; strain specificity; commercial kits; Candida auris; Fungiplex Candida Auris; AurisID

1. Introduction

Candida spp. are the most common causative agents of fungal infections in humans, ranging from local skin colonisation to blood stream infections with high mortality rates [1]. Whereas the most common species C. albicans can usually be successfully treated with antifungal agents, other species such as C. auris, C. glabrata, and C. krusei may be less susceptible or resistant to antifungals including different azoles or amphotericin B [2–6]. C. auris was first reported in 2009 and infections are particularly challenging to treat [7]. Besides the limited therapeutic options, C. auris shows high transmission rates in nosocomial environments [8] regularly leading to hospital outbreaks, possibly due to effective
biofilm formation on biotic and abiotic surfaces [9]. These two characteristics—multidrug resistance and effective transmission—underline the need for rapid and reliable detection of \textit{C. auris} in clinical samples.

Misidentification of pathogens in routine laboratories can have serious consequences for medical treatment and outcome, especially in case of strain-specific virulence properties [10]. In particular, conventional microbiology techniques are prone to errors. \textit{C. auris} shows strong sequence homology to other \textit{Candida} species like \textit{C. lusitaniae}, \textit{C. haemulonii}, \textit{C. pseudoaemulonii} etc. [11–13], which leads to high rates of misidentifications [14–16]. Biochemical identification of \textit{C. auris} isolates by the commercial system API ID 32C (Biomérieux) resulted in misidentification as \textit{C. sake} or \textit{C. intermedia} in 83% or 17% of the samples tested, respectively [17]. Even with matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) correct identification of \textit{C. auris} was not achieved in all cases [17], often due to incomplete databases [16,18]. Furthermore, both biochemical and MALDI-TOF based identification require previous cultivation of the pathogen, which may lead to delayed detection [19].

Molecular methods, in turn, could rapidly detect \textit{C. auris} directly from clinical samples. By sequence analysis and specific primer design, adequate detection and differentiation of \textit{C. auris} from other \textit{Candida} species using PCR techniques has been achieved [20]. Nevertheless, the establishment and validation of protocols using in house primers are time consuming and require deep methodological knowledge. Therefore, several commercially available and user-friendly qPCR kits for the detection of \textit{C. auris} have been developed. So far, data on the performance of these kits is scarce. In this work the performance of the kits Fungiplex \textit{Candida Auris} RUO Real-Time PCR kit (Bruker, Bremen, Germany) and \textit{AurisID} (OLM, Newcastle Upon Tyne, UK) was evaluated, using genomic DNA of 29 molecularly characterized \textit{C. auris} isolates from all five different clades as well as DNA from eight other \textit{Candida} species.

2. Material and Methods

The commercial qPCR kits \textit{AurisID} (OLM, Newcastle Upon Tyne, UK) and Fungiplex \textit{Candida auris} RUO Real Time PCR (Bruker, Bremen, Germany; further referred to as Fungiplex CaRT) were challenged with genomic DNA from pure cultures of 29 molecularly characterized \textit{C. auris} isolates [17,21,22] (Table S1). The challenge collection comprised isolates of all five clades with the following distribution: clade I: 17, clade II: 2, clade III: 5, clade IV: 4, clade V: 1. One isolate of each of the closely related \textit{Candida} species \textit{C. pseudoaemulonii}, \textit{C. haemulonii} and \textit{C. duobushaemulonii} as well as two isolates each of more distantly related \textit{Candida} species (\textit{C. albicans}, \textit{C. glabrata}, \textit{C. tropicalis}, \textit{C. krusei} and \textit{C. parapsilosis}) were additionally tested to determine the specificity of the tests.

Isolates were cultured on CHROMagar \textit{Candida} (Mast Group, Reinfeld, Germany) at 37 °C for 24 h. Subsequently, DNA was isolated using the DNeasy UltraClean Microbial Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. A baseline dilution of 10 ng DNA/µL was created for each sample, as determined by NanoDrop One (Thermo Fisher Scientific, Waltham, MA, USA). Genome copies were calculated using the formula copy number = (amount DNA [ng] * $6.022 \times 10^{23})/(length [bp] \times 1 \times 10^9 * 650)$ and a genome size of 12.1 Mb for \textit{C. auris} [13].

To determine the specificity of the assays, DNA of the control samples was tested with both kits at concentrations of 60 ng DNA/reaction (ca. $5 \times 10^6$ copies/reaction). In case of false positive results, serial 10-fold dilutions were tested up to the dilution level at which correct negative results were obtained in two out of two independent runs using DNA originating from the same extraction.

To determine the limit of detection (LoD), serial 10-fold dilutions of DNA, starting with ca. $5 \times 10^6$ genome copies/reaction were examined for all isolates. If two out of two or two out of three independent runs showed positive results, the respective isolate was counted as positive for the genome copy number of this dilution. Replicates were run with DNA originating from the same extraction. The limit of detection was calculated
as previously described by Forootan et al. [23]. Briefly, based on the number of positive isolates at the respective copy number, a replicate standard curve was generated using Prism 8.1 (GraphPad, San Diego, CA, USA) and the LoD threshold determined which gave 95% positive PCR results (Figure S1).

To assess the impact of human DNA on the tests, human blood was spiked with a suspension of C. auris. Starting from a suspension equivalent to a 0.5 McFarland standard, a 10-fold dilution series of this suspension was prepared up to a dilution of 1:10⁴ and added to human blood at a ratio of 1:10. Preliminary experiments showed that this equals roughly concentrations from 10 to 100,000 colony forming units (CFU)/mL. Exact CFU/mL concentration was determined by plating 100 µL of the spiked blood samples on Columbia Blood Agar and Malt Extract Agar plates and counting the colonies after 48 h incubation at 37 °C. DNA was extracted from 200 µL of the respective spiked blood samples plus two pure blood samples using the QIAamp DNA Mini Kit (Qiagen). DNA was eluted in 200 µL buffer and used for qPCR runs without further dilution steps. All qPCR runs were performed on an ABI7500 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). Amplification protocols are shown in Table S2.

3. Results

3.1. Evaluation of Species Specificity

To assess specificity, both kits were challenged with high amounts of genomic DNA (ca. 5 × 10⁶ copies/reaction) extracted from five C. auris isolates of all five clades. Furthermore, three isolates of the closely related species C. haemulonii, C. duobushaemulonii and C. pseudohaemulonii as well as 10 isolates of the more distantly related species C. albicans, C. glabrata, C. krusei, C. parapsilosis and C. tropicalis were tested as controls.

All five C. auris samples were correctly identified as positive by both assays. While no false-positive results were obtained with the Fungiplex CaRT kit and AurisID for less related Candida species, samples of C. haemulonii, C. duobushaemulonii and C. pseudohaemulonii gave rise to false-positive results with AurisID. Serial dilutions of genomic DNA were used to determine thresholds for false positivity. When a maximum of ca. 5 × 10⁵ copies/reaction for C. haemulonii and C. pseudohaemulonii and ca. 5 × 10⁴ copies/reaction for C. duobushaemulonii were employed, no false-positive results were recorded (Table S3).

3.2. Determination of Detection Limits

To determine the detection limits of the assay, 29 C. auris isolates were tested in at least two replicates using both kits (Figure 1). Whereas AurisID identified all strains as C. auris-positive at DNA amounts of ca. 5 copies/reaction or lower, Fungiplex CaRT detected all tested samples at amounts of ca. 50 copies/reaction and 72% of all isolates (21/29) at 5 copies/reaction. At further dilutions equivalent to ca. 0.5 or 0.05 copies/reaction, AurisID was positive in 69% (20/29) or 3% (1/29) of all samples, while no positive results were obtained with Fungiplex CaRT. Based on these results the LoD was calculated as 1 copy/reaction for AurisID and 9 copies/reaction for Fungiplex CaRT (Figure S1).

To determine the impact of human DNA on C. auris detection, DNA extracted from C. auris cultures of two isolates (381 and 382) and DNA from human blood were combined at a ratio of 1:10. Serial dilutions of the DNA mixture were tested with the PCR assays. The Fungiplex CaRT kit detected both isolates at amounts of ca. 50 copies/reaction and the AurisID at ca. 5 copies/reaction (Table 1), indicating no significant inhibition effect of human DNA on the assay.
Isolate Fungi ~3 2021, 7, 154, x x ~32 Fungiplex CFU REVIEW Reaction Table 4. Discussion

Table 1. Performance of PCR assays on human blood. Threshold for PCR positivity for two isolates using (a) spiked blood samples and (b) mixed DNA (C. auris cultures/blood).

| Isolate | (a) Viable CFU/Reaction for C. auris-Spiked Blood Samples | (b) Copies/Reaction Determined for Mixed DNA C. auris/Blood |
|---------|---------------------------------------------------------|-------------------------------------------------------------|
|         | AurisID Fungiplex CaRT                                  | AurisID Fungiplex CaRT                                      |
| 381     | ~3 ~32                                                  | ~5 ~50                                                      |
| 382     | ~2 ~45                                                  | ~5 ~50                                                      |

For further evaluation of the performance on clinical samples, human blood was spiked with a dilution series of the same two C. auris isolates and DNA was extracted directly from the spiked samples. C. auris could be detected by both kits in a dilution dependent manner. Human DNA and blood components did not interfere with C. auris detection. Comparable to assays from pure C. auris cultures, detection limits for the two spiked blood samples were around 10-fold higher for Fungiplex CaRT compared to AurisID (ca. 32/45 CFU/reaction for Fungiplex CaRT and 3/2 CFU/reaction for AurisID) (Table 1). Furthermore, pure blood samples did not lead to false-positive results or inhibition of the PCR assays.

3.3. Impact of C. auris Clade on Performance

Since C. auris clades could impact detection by PCR, obtained data was additionally analysed after stratification by clades (Table S4).

Interestingly, at ca. 5 copies/reaction 82% (14/17) of the samples of clade I were tested positive with Fungiplex CaRT compared to 25% (1/4) of the samples in clade IV. However, this difference did not reach statistical significance (p = 0.0526 by Fisher’s exact test). No correlation between clade and detection limit was observed at any other concentration for both assays (Table S4).

4. Discussion

To the best of our knowledge, this is the first systematic evaluation of two commercially available PCR based kits for C. auris detection, the AurisID and Fungiplex CaRT. AurisID demonstrated higher sensitivity with a LoD of 1 copy/reaction compared to 9 copies/reaction for Fungiplex CaRT. At very high amounts of ca. 5 × 10^6 copies/reaction or 5 × 10^5 copies/reaction, AurisID gave rise to false-positive results for closely related
Candida species, in contrast to Fungiplex CaRT. Likely, this is of little diagnostic relevance as clinical specimen contain much lower amounts of C. auris DNA compared to purified DNA from colonies.

When analysing spiked blood samples, a similar difference in the detection limit of the two kits was observed. The results obtained with these commercially available kits show good sensitivity as described in previous studies with in house assays using Taq-Man chemistry-based PCR [24]. The authors determined a detection limit of 1 CFU/reaction. High sensitivity was also proven for the commercial kit GPS™ MONODOSE CanAur dtec-qPCR kit (Alicante, Spain), which yielded positive results for samples with 5 to 10 copies of the DNA template [25]. In the present study, LoDs of 1 copy/reaction (AurisID) and 9 copies/reaction (Fungiplex CaRT) were recorded and 2/3 CFU/reaction (AurisID) and 32/45 CFU/reaction (Fungiplex CaRT) in the spiked blood experiments. However, a comparison of the data to the aforementioned studies is difficult given the varying efficiency of DNA extraction and a different experimental setup.

The commercially available kits assessed in the present study may reduce hands-on-time even for inexperienced users due to easy-to-follow protocols. In addition, commercially available assays allow high reproducibility and consistency [25].

AurisID provided false-positive results for closely related Candida species when high DNA concentrations of ca. $5 \times 10^6$ and $5 \times 10^5$ copies/reaction were used. It should be noted that the recommended cycling protocol had to be changed because the ramp rates of the ABI platform used were not sufficiently high. Therefore, the annealing/synthesis step was extended from 20 to 30 s, which could have increased unspecific primer binding. Therefore, the assay was additionally run on the Rotor-Gene Q cycler (Qiagen, Hilden, Germany), which could be operated with the recommended protocol. However, false-positive results were obtained for the same samples and with the same DNA concentrations as with the ABI platform. Therefore, false-positive results are likely caused by less specific oligonucleotide binding of the AurisID assay. While exact primer and probe sequences have not been disclosed by the manufacturers, both kits have different target regions, with the 28S ribosomal gene region for AurisID and the mating locus alpha for Fungiplex CaRT. Since 28S is a multicopy target, it might explain the lower LoD of 1 copy/reaction. In contrast, the copy number of the exact mating locus alpha target used for Fungiplex CaRT is not known.

In previous studies it was shown that identification success by biochemical methods may depend on the specific clade analysed [26]. In contrast, we did not observe any significant clade-specific difference in performance with these two molecular assays. A numerically higher detection of clade I compared to clade IV by Fungiplex CaRT was noted at ca. 5 copies/reaction which should be analysed with a larger number of samples in future studies. However, for some clades, particularly clade II and V, only small numbers of samples were included in this study so that no definite conclusions can be drawn.

Some aspects that could potentially affect the final results have not been considered in our evaluation. For comparison reasons, both assays were challenged with the same amount of DNA and a higher sensitivity was recorded for AurisID. However, it has to be noted that higher template volumes (10 µL instead of 6 µL) can be used for the Fungiplex CaRT assay, which will likely improve detection when working with clinical samples. In the present study, DNA extracted mainly from pure cultures was used. However, various specimen in diagnostic routine may contain microbiota, host cells or other substances, which could possibly impact the results. Since the prevalence of C. auris infection or colonization is very low in Germany, DNA from cultured isolates instead of clinical specimen had to be used for this evaluation. Successful detection of C. auris from spiked blood samples and from mixed DNA extracted from C. auris and human blood indicated that both assays work well in the presence of human DNA and likely for other clinical samples. However, future studies are needed to validate the performance of both assays directly on various clinical specimen and their usefulness in the hospital setting. In addition, DNA extraction methods differ in terms of efficacy as well as stability of the extracted nucleic acids and therefore
also may influence the overall performance. Furthermore, DNA extraction kits used in diagnostic laboratories are usually optimized for isolation of bacterial or viral DNA. Fungal cells have a thicker cell wall and may therefore require different lysis strategies [27]. Before using any C. auris PCR kits on clinical samples, laboratories should assess the performance of their DNA extraction kit for clinical mycological samples.

In summary, based on our results, AurisID and Fungiplex CaRT are suitable for identification of C. auris even at low DNA concentrations. AurisID showed a higher sensitivity for C. auris detection and Fungiplex CaRT a higher specificity. Both assays have easy-to-follow protocols, thus facilitating reliable diagnostics of C. auris infections.

Supplementary Materials: The following are available online at https://www.mdpi.com/2309-608X/7/2/154/s1, Figure S1: Determination of the limit of detection for (A) AurisID and (B) Fungiplex CaRT. The LoD was calculated as the threshold which resulted in 95% positive samples, Table S1: C. auris isolates used in this study. BSI, blood stream infection, Table S2: qPCR protocols applied for the different kits, Table S3: Thresholds for false-positive results. Both kits were challenged with serial dilutions of DNA extracted from eight negative controls, Table S4: PCR positivity in relation to C. auris clade. Shown is the number of correctly identified isolates from each clade at the respective copy number.

Author Contributions: The authors of this manuscript contributed as follows: Conceptualization: A.H. Data curation: J.N., A.B. and J.N. Formal analysis: J.N. and J.S. Funding acquisition: A.H. Investigation: J.S., A.B., P.W. and G.P. Methodology: A.H., J.S., G.P., J.F.M. and O.K. Project administration: A.H. and J.S. Resources: A.H. Supervision: A.H. Validation: A.H., J.S. and J.N. Visualization: J.N. and A.H. Writing—original draft: J.N. and J.S. Writing—review & editing: A.H., G.P., P.W., J.F.M., O.K., J.S., A.B. and J.N. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the German Centre for Infection Research (DZIF) under grant No. 08706.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in Figure 1, Tables S3 and S4. Raw data are available on reasonable request from the corresponding author.

Acknowledgments: PCR kits were provided at reduced costs by OLM diagnostics and Bruker. We thank Ronny Martin for helpful discussions on Candida genetics.

Conflicts of Interest: The authors declare that there are no conflict of interest.

References
1. Vincent, J.L.; Rello, J.; Marshall, J.; Silva, E.; Anzueto, A.; Martin, C.D.; Moreno, R.; Lipman, J.; Gomersall, C.; Sakr, Y.; et al. International study of the prevalence and outcomes of infection in intensive care units. J. Am. Med. Assoc. 2009, 302, 2323–2329. [CrossRef]
2. Pfaffer, M.; Diekema, D. Twelve years of fluconazole in clinical practice: Global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. 2004, 10, 11–23. [CrossRef]
3. Vermitsky, J.P.; Edlind, T.D. Azole resistance in Candida glabrata: Coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor. Antimicrob. Agents Chemother. 2004, 48, 3773–3781. [CrossRef] [PubMed]
4. Young, L.Y.; Hull, C.M.; Heitman, J. Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae. Antimicrob. Agents Chemother. 2003, 47, 2717–2724. [CrossRef]
5. Orozco, A.S.; Higginbotham, L.M.; Hitchcock, C.A.; Parkinson, T.; Falconer, D.; Ibrahim, A.S.; Ghannoum, M.A.; Filler, S.G. Mechanism of fluconazole resistance in Candida krusei. Antimicrob. Agents Chemother. 1998, 42, 2645–2649. [CrossRef]
6. Chowdhary, A.; Prakash, A.; Sharma, C.; Kordalewska, M.; Kumar, A.; Sarma, S.; Tarai, B.; Singh, A.; Upadhyaya, G.; Upadhyay, S.; et al. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–2017) in India: Role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J. Antimicrob. Chemother. 2018, 73, 891–899. [CrossRef]
7. Kean, R.; Brown, J.; Gulmez, D.; Ware, A.; Ramage, G. Candida auris: A decade of understanding of an enigmatic pathogenic yeast. J. Fungi 2020, 6, 30. [CrossRef] [PubMed]
8. Schelenz, S.; Hagen, F.; Rhodes, J.L.; Abdolrasouli, A.; Chowdhary, A.; Hall, A.; Ryan, L.; Shackleton, J.; Trimlett, R.; Meis, J.F.; et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob. Resist Infect. Control 2016, 5, 1–7. [CrossRef]
9. Chatzimoschou, A.; Giampani, J.F.; Meis, E.R. Activities of nine antifungal agents against Candida auris biofilms. Mycoses 2021, 64, 1–13. [CrossRef]

10. Zong, Z.; Wang, X.; Deng, Y.; Zhou, T. Misidentification of Burkholderia pseudomallei as Burkholderia cepacia by the VITEK 2 system. J. Med. Microbiol. 2012, 61, 1483–1484. [CrossRef]

11. Sharma, C.; Kumar, N.; Pandey, R.; Meis, J.F.; Chowdhary, A. Whole genome sequencing of emerging multidrug resistant Candida auris isolates in India demonstrates low genetic variation. New Microbes New Infect. 2016, 13, 77–82. [CrossRef]

12. Kathuria, S.; Singh, P.K.; Sharma, C.; Prakash, A.; Masih, A.; Kumar, A.; Meis, J.F.; Chowdhary, A. Multidrug-resistant Candida auris misidentified as Candida haemulonii: Characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method CL. J. Clin. Microbiol. 2015, 53, 1823–1830. [CrossRef]

13. Muñoz, J.F.; Gade, L.; Chow, N.A.; Loparev, V.N.; Juieng, P.; Berkow, E.L.; Farrer, R.A.; Litvintseva, A.P.; Cuomo, C.A. Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species. Nat. Commun. 2018, 9, 1–13. [CrossRef]

14. Snayd, M.; Dias, F.; Ryan, R.W.; Clout, D.; Banach, D.B. Misidentification of Candida auris by RapID yeast plus, a commercial, biochemical enzyme-based manual rapid identification system. J. Clin. Microbiol. 2018, 56, e00080-18. [CrossRef]

15. Kordalewska, M.; Perlin, D.S. Identification of drug resistant Candida auris. Front. Microbiol. 2019, 10, 1918. [CrossRef] [PubMed]

16. Mizusawa, M.; Miller, H.; Green, R.; Lee, R.; Durante, M.; Perkins, R.; Hewitt, C.; Simner, P.J.; Carroll, K.C.; Hayden, R.T.; et al. Can multidrug-resistant Candida auris be reliably identified in clinical microbiology laboratories? J. Clin. Microbiol. 2017, 55, 638–640. [CrossRef] [PubMed]

17. Hamprecht, A.; Barber, A.E.; Mellinlinghoff, S.C.; Thelen, P.; Walthier, G.; Yu, Y.; Neurgaonkar, P.; Dandekar, T.; Cornely, O.A.; Martin, R.; et al. Candida auris in Germany and previous exposure to foreign healthcare. Emerg. Infect. Dis. 2019, 25, 1763. [CrossRef] [PubMed]

18. Buil, J.B.; van der Lee, H.A.L.; Curs-Breuker, I.; Verweij, P.E.; Meis, J.F. External quality assessment evaluating the ability of Dutch clinical microbiological laboratories to identify Candida auris. J. Fungi 2019, 5, 94. [CrossRef] [PubMed]

19. Mancini, N.; Carletti, S.; Ghidoli, N.; Cichero, P.; Burioni, R.; Clementi, M. The era of molecular and other non-culture-based methods in diagnosis of sepsis. Clin. Microbiol. Rev. 2010, 23, 235–251. [CrossRef]

20. Kordalewska, M.; Zhao, Y.; Lockhart, S.R.; Chowdhary, A.; Berrio, I.; Perlin, D.S. Rapid and accurate molecular identification of the emerging multidrug-resistant pathogen Candida auris. J. Clin. Microbiol. 2017, 55, 2445–2452. [CrossRef]

21. De Groot, T.; Puts, Y.; Berrio, I.; Chowdhary, A.; Meis, J.F. Development of Candida auris short tandem repeat typing and its application to a global collection of isolates. MBio 2020, 11, e02971-19. [CrossRef]

22. Alfouzan, W.; Ahmad, S.; Dhar, R.; Asadzadeh, M.; Almerdasi, N.; Abdo, N.M.; Joseph, L.; de Groot, T.; Alali, W.Q.; Khan, Z.; et al. Molecular epidemiology of Candida auris outbreak in a major secondary-care hospital in Kuwait. J. Fungi 2020, 6, 307. [CrossRef] [PubMed]

23. Forootan, A.; Sjöback, R.; Björkman, T.; Sjögreen, B.; Linz, L.; Kubista, M. Methods to determine limit of detection and limit of quantification in quantitative real-time PCR (qPCR). Biomol. Detect. Quantif. 2017, 12, 1–6. [CrossRef]

24. Leach, L.; Zhu, Y.; Chaturvedi, S. Development and validation of a real-Time PCR assay for rapid detection of Candida auris from surveillance samples. J. Clin. Microbiol. 2018, 56, e01223-17. [CrossRef]

25. Martinez-Murcia, A.; Navarro, A.; Bru, G.; Chowdhary, A.; Hagen, F.; Meis, J.F. Internal validation of GPS™ MONODOSE CanAur dtec-qPCR kit following the UNE/EN ISO/IEC 17025:2005 for detection of the emerging yeast Candida auris. Mycoses 2018, 61, 877–884. [CrossRef]

26. Ambaraghassi, G.; Dufresne, P.J.; Dufresne, S.F.; Vallières, É.; Muñoz, J.F.; Cuomo, C.A.; Berkow, E.L.; Lockhart, S.R.; Luong, M.-L. Identification of Candida auris by use of the updated Vitek 2 yeast identification system, version 8.01: A multilaboratory evaluation study. J. Clin. Microbiol. 2019, 57, e00884-19. [CrossRef] [PubMed]

27. Fredricks, D.N.; Smith, C.; Meier, A. Comparison of six DNA extraction methods for recovery of fungal DNA as assessed by quantitative PCR. J. Clin. Microbiol. 2005, 43, 5122–5128. [CrossRef] [PubMed]